



Inflammation, Immunity, and Cancer Progression

Guest Editors:

Dr. Deepak Parashar

Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Dr. Vivek K. Kashyap

Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX, USA

Dr. Subhash Tripathi

Seattle Children's Research Institute, Seattle, CA, USA

Deadline for manuscript submissions:

closed (31 May 2024)

Message from the Guest Editors

Chronic inflammation plays a significant role in cancer initiation, progression, metastasis, and chemoresistance. Additionally, cancer-related inflammation is the seventh hallmark of cancer and is associated with genetic instability. Genomic and epigenomic mechanisms are essential to establishing cellular programs in cancer and immune cells. The dysregulation of these mechanisms contributes to tumor growth.

This Special Issue will highlight the latest experimental advances and technical developments in genomics and epigenomics, gene editing, gene delivery, and therapeutic approaches for studying immune regulation in immune-mediated diseases, including autoimmunity and cancer.

Manuscript submissions presenting outstanding contributions to cancer and immunity fields, including, but not limited to, the following topics:

- Inflammation in cancer immunity;
- Transcriptional and epigenetic regulations in cancer cells and immune cell differentiation and development;
- Transcriptomics and epigenomics of immune-mediated diseases;
- Immunometabolism;
- Pharmacogenomic of diseases;
- Integration of Bioinformatics Data.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)